• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk of Stroke and Major Bleeding with Vitamin-K Antagonist Use after Mitral Valve Repair
CONCLUSIONS: Our study suggests that VKA after MVr does not reduce risk of cerebral embolic events but is associated with increased risk of major bleeding events.PMID:36223805 | DOI:10.1016/j.athoracsur.2022.09.038
Source: The Annals of Thoracic Surgery - October 12, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Chase R Brown Alexandra E Sperry William G Cohen Jason J Han Fabliha Khurshan Peter Groeneveld Nimesh Desai Source Type: research

Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review
CONCLUSION: Cumulative data analysis reveals that DOAC may provide an effective and safe alternative to VKA in patients with AF after surgically implanted bioprosthetic heart valves or repair with AF. Within a relatively heterogeneous study population, this meta-analysis shows a risk reduction of major bleedings and thromboembolic stroke or systemic embolisms for DOAC.PMID:35481366 | DOI:10.1177/17539447221093963
Source: Adv Data - April 28, 2022 Category: Epidemiology Authors: Stephen Gerfer Ilija Djordjevic Kaveh Eghbalzadeh Navid Mader Thorsten Wahlers Elmar Kuhn Source Type: research

Non-Vitamin K Antagonists versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: a Systematic Review and Meta-Analysis
Patients with bioprosthetic heart valves and valve repair with concomitant atrial fibrillation are at an increased risk of thromboembolic events.1-5 Until recently, there was a paucity of randomized data to guide the optimal anticoagulation strategy in this patient population. In a prior meta-analysis of 4 randomized studies in patients with atrial fibrillation and valvular heart disease, excluding significant mitral stenosis and mechanical valves, there was a significant reduction in the risk of stroke or systemic embolism with non-vitamin K antagonist oral anticoagulants (NOACs) vs.
Source: The American Journal of Medicine - October 7, 2021 Category: General Medicine Authors: Rhanderson Cardoso, Caique M.P. Ternes, Gustavo B. Justino, Amanda Fernandes, Ana Vitoria Rocha, Leonardo Knijnik, Andre d'Avila, Renato D. Lopes Tags: Clinical Research Study Source Type: research

Comparison of outcomes of direct-acting oral anticoagulants vs. vitamin K antagonists in patients with bioprosthetic heart valves or valve repair: a systematic review and meta-analysis
CONCLUSIONS: Findings suggest that the use DOACs in patients with AF with bioprosthetic valve replacement or repair is comparatively better than vitamin K antagonists in reducing the risk of bleeding and thrombo-embolic events. Future studies with a randomized design and larger sample sizes are needed to further substantiate these findings.PMID:34355372 | DOI:10.26355/eurrev_202108_26457
Source: European Review for Medical and Pharmacological Sciences - August 6, 2021 Category: Drugs & Pharmacology Authors: L-L Tang S-W Liang H-L Shi J-J Ye Source Type: research

Pages: 1  2  3